{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T11:59:03Z","timestamp":1772884743601,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T00:00:00Z","timestamp":1671235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T00:00:00Z","timestamp":1671235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003819","name":"Natural Science Foundation of Hubei Province","doi-asserted-by":"publisher","award":["2018CFB147"],"award-info":[{"award-number":["2018CFB147"]}],"id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Yichang Medical and Health Research Project","award":["No. A20-2-005"],"award-info":[{"award-number":["No. A20-2-005"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To investigate the prognostic value of fluroine-18 fluorodexyglucose positron emission tomography\/computed tomography (<jats:sup>18<\/jats:sup>F-FDG PET\/CT) semi-quantitative parameter in newly diagnosed multiple myeloma (NDMM) and to design a new staging system including <jats:sup>18<\/jats:sup>F-FDG PET\/CT semi-quantitative parameters for NDMM.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A total of 38 NDMM patients who underwent <jats:sup>18<\/jats:sup>F-FDG PET\/CT examination in Yichang Central People\u2019s Hospital from February 2014 to April 2021 were collected. The relationship between the characteristics of <jats:sup>18<\/jats:sup>F-FDG PET\/CT (metabolic tumor volume of all lesions (aMTV), total lesion glycolysis of all lesions (aTLG), maximum standardized uptake values (SUVmax) of the lesion with largest MTV (mSUVmax), extramedullary disease (EMD), focal lesions (FLs)), the laboratory parameters, and prognostic parameters (progression-free survival (PFS) and overall survival (OS)) were analyzed retrospectively. SPSS 25.0 statistical software was used for statistical processing, Kaplan\u2013Meier method was used for survival analysis, Log-rank method was used for univariate analysis, and Cox proportional risk model was used for multivariate analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Univariate analysis showed that aMTV\u2009\u2265\u200990.97cm<jats:sup>3<\/jats:sup>, aTLG\u2009\u2265\u2009283.31\u00a0g, hemoglobin (Hb)\u2009&lt;\u2009100\u00a0g\/L, focal lesions (FLs)\u2009\u2265\u200910, (percentage of circulating plasma cells (CPC%)\u2009\u2265\u200930%, creatinine (Cr)\u2009\u2265\u2009177umol\/L, lactic dehydrogenase (LDH)\u2009\u2265\u2009250\u00a0g\/L might be the adverse prognostic factors of PFS in patients with NDMM, all <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05; aMTV\u2009\u2265\u200990.97\u00a0cm<jats:sup>3<\/jats:sup>, aTLG\u2009\u2265\u2009283.31\u00a0g, Hb\u2009&lt;\u2009100\u00a0g\/L, FLs\u2009\u2265\u200910, mSUVmax\u2009\u2265\u20095.8, the presence of extramedullary disease (EMD) and PCPs\u2009\u2265\u200930% may be adverse prognostic factors for OS in patients with NDMM, all <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05. Multivariate regression analysis showed that aMTV\u2009\u2265\u200990.97\u00a0cm<jats:sup>3<\/jats:sup> was an independent risk factor for PFS in NDMM patients, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05; aMTV\u2009\u2265\u200990.97\u00a0cm<jats:sup>3<\/jats:sup>, mSUVmax\u2009\u2265\u20095.8, and the presence of EMD were independent risk factors for OS in the NDMM patients, all <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05. According to the multivariate analysis results of OS, the New stage (NS) was performed. The 3-year OS rates of stage I, stage II, and stage III in NDMM patients were 100.0, 53.5, and 32.1%, respectively, <jats:italic>p<\/jats:italic>\u2009=\u20090.000.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>aMTV can predict PFS and OS of NDMM patients better than other parameters. NS which combined with aMTV can predict OS of NDMM patients better and can provide an accurate and simple method for risk stratification of NDMM patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12149-022-01812-x","type":"journal-article","created":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T17:02:31Z","timestamp":1671296551000},"page":"155-165","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Prognostic value of semi-quantitative parameters of 18F-FDG PET\/CT in newly diagnosed multiple myeloma patients"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2482-7518","authenticated-orcid":false,"given":"Baoyu","family":"Wan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Song","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengyi","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenli","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,17]]},"reference":[{"issue":"6","key":"1812_CR1","doi-asserted-by":"publisher","first-page":"e302","DOI":"10.1016\/S1470-2045(19)30309-2","volume":"20","author":"J Hillengass","year":"2019","unstructured":"Hillengass J, Usmani S, Rajkumar SV, et al. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncol. 2019;20(6):e302\u201312. https:\/\/doi.org\/10.1016\/S1470-2045(19)30309-2.","journal-title":"Lancet Oncol"},{"issue":"12","key":"1812_CR2","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538\u201348. https:\/\/doi.org\/10.1016\/S1470-2045(14)70442-5.","journal-title":"Lancet Oncol"},{"issue":"4","key":"1812_CR3","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1111\/bjh.14081","volume":"174","author":"KK Abbi","year":"2016","unstructured":"Abbi KK, Silverman M, Farooq U, et al. Potential pitfalls of serum free light chain analysis to assess treatment response for multiple myeloma. Br J Haematol. 2016;174(4):536\u201340. https:\/\/doi.org\/10.1111\/bjh.14081.","journal-title":"Br J Haematol"},{"issue":"12","key":"1812_CR4","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1002\/ajh.25279","volume":"93","author":"MA Aljama","year":"2018","unstructured":"Aljama MA, Sidiqi MH, Buadi FK, et al. Utility and prognostic value of (18) F-FDG positron emission tomography-computed tomography scans in patients with newly diagnosed multiple myeloma. Am J Hematol. 2018;93(12):1518\u201323. https:\/\/doi.org\/10.1002\/ajh.25279.","journal-title":"Am J Hematol"},{"issue":"4","key":"1812_CR5","doi-asserted-by":"publisher","first-page":"250","DOI":"10.4110\/in.2017.17.4.250","volume":"17","author":"K Batsukh","year":"2017","unstructured":"Batsukh K, Lee SE, Min GJ, et al. Distinct clinical outcomes between paramedullary and extramedullary lesions in newly diagnosed multiple Myeloma. Immune Netw. 2017;17(4):250\u201360. https:\/\/doi.org\/10.4110\/in.2017.17.4.250.","journal-title":"Immune Netw"},{"issue":"4","key":"1812_CR6","doi-asserted-by":"publisher","first-page":"581","DOI":"10.3892\/etm.2012.663","volume":"4","author":"K Haraguchi","year":"2012","unstructured":"Haraguchi K, Uto H, Ohnou N, et al. Serum prohepcidin levels are potential prognostic markers in patients with multiple myeloma. Exp Ther Med. 2012;4(4):581\u20138. https:\/\/doi.org\/10.3892\/etm.2012.663.","journal-title":"Exp Ther Med"},{"issue":"1","key":"1812_CR7","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s00259-018-4114-0","volume":"46","author":"SH Jung","year":"2019","unstructured":"Jung SH, Kwon SY, Min JJ, et al. (18)F-FDG PET\/CT is useful for determining survival outcomes of patients with multiple myeloma classified as stage II and III with the revised International staging system. Eur J Nucl Med Mol Imaging. 2019;46(1):107\u201315. https:\/\/doi.org\/10.1007\/s00259-018-4114-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"1812_CR8","doi-asserted-by":"publisher","first-page":"254","DOI":"10.7150\/thno.13921","volume":"6","author":"C Lapa","year":"2016","unstructured":"Lapa C, Knop S, Schreder M, et al. 11C-methionine-PET in multiple myeloma: correlation with clinical parameters and bone marrow involvement. Theranostics. 2016;6(2):254\u201361. https:\/\/doi.org\/10.7150\/thno.13921.","journal-title":"Theranostics"},{"issue":"3","key":"1812_CR9","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3348\/kjr.2018.19.3.481","volume":"19","author":"SH Moon","year":"2018","unstructured":"Moon SH, Choi WH, Yoo IR, et al. Prognostic value of baseline (18)F-fluorodeoxyglucose PET\/CT in patients with multiple myeloma: a multicenter cohort study. Korean J Radiol. 2018;19(3):481\u20138. https:\/\/doi.org\/10.3348\/kjr.2018.19.3.481.","journal-title":"Korean J Radiol"},{"issue":"25","key":"1812_CR10","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1200\/JCO.2017.72.2975","volume":"35","author":"P Moreau","year":"2017","unstructured":"Moreau P, Attal M, Caillot D, et al. Prospective evaluation of magnetic resonance imaging and [(18)F] Fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM\/DFCI 2009 trial: results of the imajem study. J Clin Oncol. 2017;35(25):2911\u20138. https:\/\/doi.org\/10.1200\/JCO.2017.72.2975.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1812_CR11","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/ejh.13006","volume":"100","author":"H Tu","year":"2018","unstructured":"Tu H, He Y, Huang T, et al. Predictive value of (18) F-FDG PET\/CT scanning in combination with clinical parameters in patients with newly diagnosed multiple myeloma. Eur J Haematol. 2018;100(2):189\u201397. https:\/\/doi.org\/10.1111\/ejh.13006.","journal-title":"Eur J Haematol"},{"issue":"7","key":"1812_CR12","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1182\/blood-2018-08-825356","volume":"133","author":"E Zamagni","year":"2019","unstructured":"Zamagni E, Tacchetti P, Cavo M. Imaging in multiple myeloma: How? When? Blood. 2019;133(7):644\u201351. https:\/\/doi.org\/10.1182\/blood-2018-08-825356.","journal-title":"Blood"},{"key":"1812_CR13","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.critrevonc.2016.03.006","volume":"101","author":"G Rubini","year":"2016","unstructured":"Rubini G, Niccoli-Asabella A, Ferrari C, et al. Myeloma bone and extra-medullary disease: role of PET\/CT and other whole-body imaging techniques. Crit Rev Oncol Hematol. 2016;101:169\u201383. https:\/\/doi.org\/10.1016\/j.critrevonc.2016.03.006.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"6","key":"1812_CR14","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1007\/s00259-011-1738-8","volume":"38","author":"R Haznedar","year":"2011","unstructured":"Haznedar R, Aki SZ, Akdemir OU, et al. Value of 18F-fluorodeoxyglucose uptake in positron emission tomography\/computed tomography in predicting survival in multiple myeloma. Eur J Nucl Med Mol Imaging. 2011;38(6):1046\u201353. https:\/\/doi.org\/10.1007\/s00259-011-1738-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"1812_CR15","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1182\/blood-2011-06-359943","volume":"119","author":"P Pregno","year":"2012","unstructured":"Pregno P, Chiappella A, Bello M, et al. Interim 18-FDG-PET\/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. Blood. 2012;119(9):2066\u201373. https:\/\/doi.org\/10.1182\/blood-2011-06-359943.","journal-title":"Blood"},{"issue":"23","key":"1812_CR16","doi-asserted-by":"publisher","first-page":"5989","DOI":"10.1182\/blood-2011-06-361386","volume":"118","author":"E Zamagni","year":"2011","unstructured":"Zamagni E, Patriarca F, Nanni C, et al. Prognostic relevance of 18-F FDG PET\/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood. 2011;118(23):5989\u201395. https:\/\/doi.org\/10.1182\/blood-2011-06-361386.","journal-title":"Blood"},{"issue":"3","key":"1812_CR17","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","volume":"36","author":"BG Durie","year":"1975","unstructured":"Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36(3):842\u201354.","journal-title":"Cancer"},{"issue":"26","key":"1812_CR18","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1002\/1097-0142(197509)36:3<842::aid-cncr2820360303>3.0.co;2-u","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol. 2015;33(26):2863\u20139. https:\/\/doi.org\/10.1002\/1097-0142(197509)36:3%3c842::aid-cncr2820360303%3e3.0.co;2-u.","journal-title":"J Clin Oncol"},{"key":"1812_CR19","doi-asserted-by":"publisher","first-page":"4198673","DOI":"10.1155\/2018\/4198673","volume":"2018","author":"S Deng","year":"2018","unstructured":"Deng S, Zhang B, Zhou Y, et al. The role of (18)F-FDG PET\/CT in multiple myeloma staging according to IMPeTUs: comparison of the durie-salmon plus and other staging systems. Cont Med Mol Imag. 2018;2018:4198673. https:\/\/doi.org\/10.1155\/2018\/4198673.","journal-title":"Cont Med Mol Imag"},{"issue":"6","key":"1812_CR20","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1007\/s00259-019-4275-5","volume":"46","author":"Y Abe","year":"2019","unstructured":"Abe Y, Narita K, Kobayashi H, et al. Pretreatment (18)F-FDG PET\/CT combined with quantification of clonal circulating plasma cells as a potential risk model in patients with newly diagnosed multiple myeloma. Eur J Nucl Med Mol Imaging. 2019;46(6):1325\u201333. https:\/\/doi.org\/10.1007\/s00259-019-4275-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"19","key":"1812_CR21","doi-asserted-by":"publisher","first-page":"e3521","DOI":"10.1097\/MD.0000000000003521","volume":"95","author":"Y Jian","year":"2016","unstructured":"Jian Y, Chen X, Zhou H, et al. Prognostic impact of cytogenetic abnormalities in multiple myeloma: a retrospective analysis of 229 patients. Medicine (Baltimore). 2016;95(19):e3521. https:\/\/doi.org\/10.1097\/MD.0000000000003521.","journal-title":"Medicine (Baltimore)"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-022-01812-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-022-01812-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-022-01812-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T22:11:01Z","timestamp":1677017461000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-022-01812-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,17]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["1812"],"URL":"https:\/\/doi.org\/10.1007\/s12149-022-01812-x","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,17]]},"assertion":[{"value":"8 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"According to the Declaration of Helsinki, the study has been approved by the Medical Ethics Committee of Yichang Central People's Hospital (also known as the first Clinical Medical College of Three Gorges University) with approval number 2021\u2013063-01.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}